Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.3%. By the end of trading, Allergan fell 96 cents (-1%) to $91.61 on light volume. Throughout the day, 1.1 million shares of Allergan exchanged hands as compared to its average daily volume of 1.5 million shares. The stock ranged in price between $91.41-$92.41 after having opened the day at $92.12 as compared to the previous trading day's close of $92.57. Other companies within the Drugs industry that declined today were:
), down 20.7%,
), down 18.8%,
), down 18.8%, and
), down 18.4%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $28.05 billion and is part of the health care sector. The company has a P/E ratio of 27.3, above the S&P 500 P/E ratio of 17.7. Shares are up 6.4% year to date as of the close of trading on Thursday. Currently there are 16 analysts that rate Allergan a buy, no analysts rate it a sell, and seven rate it a hold.
TheStreet Ratings rates Allergan as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.
- You can view the full Allergan Ratings Report.
On the positive front,
), up 32.8%,
), up 29.1%,
), up 19.1%, and
), up 18.6%, were all gainers within the drugs industry with
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.
Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade